Why Investors Need to Take Advantage of These 2 Medical Stocks Now
Finding stocks expected to beat quarterly earnings estimates becomes an easier task with our Zacks Earnings ESP.
Exact Sciences (EXAS) Moves to Strong Buy: Rationale Behind the Upgrade
Exact Sciences (EXAS) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Will Screening Sales Drive Exact Sciences' Q3 Earnings?
Precision Oncology revenues of EXAS are likely to have been boosted by laboratory service revenues from global Oncotype DX and therapy selection tests.
Can This Beaten-Down Cathie Wood Stock Bounce Back?
An updated version of Exact Sciences' key product just got regulatory approval. That could help the healthcare stock stage a comeback.
EXAS Gains FDA Nod for Cologuard Plus, Progresses With CRC Screening
Per the findings of the pivotal BLUE-C study, the Cologuard Plus test of Exact Sciences stands out for its high sensitivity at a specificity of 94%.
FMR LLC Bolsters Stake in Exact Sciences Corp
On September 30, 2024, FMR LLC (Trades, Portfolio), a prominent investment firm, significantly increased its investment in Exact Sciences Corp (EXAS, Financial), a leader in cancer diagnostics. The firm acquired an additional 8,418,428 shares at a price of $68.12 each, elevating its total holdings to 22,042,464 shares.
Is EXAS Stock a Smart Addition to Your Portfolio Right Now?
Exact Sciences is making solid headway in promoting Cologuard as the benchmark for care.
Exact Sciences To Rally Around 33%? Here Are 10 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Wall Street Analysts Believe Exact Sciences (EXAS) Could Rally 34.33%: Here's is How to Trade
The mean of analysts' price targets for Exact Sciences (EXAS) points to a 34.3% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Exact Sciences Corporation (EXAS) at Wells Fargo 2024 Healthcare Conference - Transcript
Exact Sciences Corporation (NASDAQ:EXAS ) Wells Fargo 2024 Healthcare Conference September 5, 2024 3:45 PM ET Company Participants Aaron Bloomer - Chief Financial Officer Conference Call Participants Brandon Couillard - Wells Fargo Brandon Couillard Alright, folks. We'll go ahead and get started.
Exact Sciences (EXAS) Up 7.5% Since Last Earnings Report: Can It Continue?
Exact Sciences (EXAS) reported earnings 30 days ago. What's next for the stock?
Does Exact Sciences (EXAS) Have the Potential to Rally 34.13% as Wall Street Analysts Expect?
The average of price targets set by Wall Street analysts indicates a potential upside of 34.1% in Exact Sciences (EXAS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
